Edesa Biotech, Inc. · NASDAQ:EDSA
Edesa Biotech — Investor Presentation (August 2026)
27 slides from Edesa Biotech's investor presentation, August 2026
Slide 1: Corporate Presentation
f 3 \ | Edesa Biotech Corporate Presentation
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "
Slide 3: First-in-Class Development Pipeline
First-in-Class Development Pipeline Advancing Innovative Therapeutics for Immuno-Inflammatory Conditions Pre- Asset Program Indication Phase 1 Phase 2 Phase 3 Status Comments Clinical Initiate site Anti-CXCL10 CTA granted; IND activations and EB06 Vitiligo (mAb) in progress recruitment mid- 2026* Me
Slide 4: EB06 - Vitiligo
EB06 - Vitiligo Potential First-in-Class Anti-CXCL10 mAb
Slide 5: A Significant Unaddressed Market
A Significant Unaddressed Market Latent Market Comprised of Patients Waiting for Better Treatment Options Large Untapped Opportunity Large population but low proportion of patients seeking treatment due to lack of effective and safe treatments Diagnosed with 1.9M New therapies likely to drive market
Slide 6: Vitiligo: A Life-Altering Autoimmune Disease
Vitiligo IFNγ-CXCL10-CXCR3 Chemokine Axis Plays a Key Role A Life-Altering Autoimmune Disease in the Pathogenesis of Vitiligo High Prevalence – 0.5 to 2% Global Population 50% Onset Before Age 20; Must be Managed for Decades Associated with Type 1 Diabetes and Lupus, among others Severe Quality of L
Slide 7: EB06 – Targeting the Chemokine CXCL10
EB06 – Targeting the Chemokine CXCL10 Monoclonal Antibody that Directly Binds CXCL10 with High Affinity and Blocks it from Binding to CXCR3 IFNγ CXCL10 EB06 Drug Profile CXCR3A CXCR3B A fully human IgG1k monoclonal antibody Binds specifically to CXCL10 with high Ca2+ flux MAPK Akt PKA affinity Seque
Slide 8: CXCL10 Therapeutic Potential
CXCL10 Therapeutic Potential Therapeutically Targeting - Observed in Preclinical Studies 1 2 1 Melanocyte Apoptosis CXCL10/CXC3B mediates melanocyte apoptosis and activates anti-melanocytic CD8+ T-cells via CXCR3A 2 Knockout Mice CXCL10 -/- mice do not develop vitiligo 3 4 Reverse Depigmentation 3 A
Slide 9: Targeting the IFNγ-CXCL10-CXCR3 Chemokine Axis
Targeting the IFNγ-CXCL10-CXCR3 Chemokine Axis EB06 is an anti-CXCL10 Monoclonal Antibody that Can Act on Different Stages of Vitiligo Non-Lesional (Innate) Lesional (Adaptive) EB06 inhibits: 1 CXCL10/CXCR3B-mediated melanocyte apoptosis and antigen presentation 2 CXCL10/CXCR3A-mediated trafficking
Slide 10: EB06 Positioning – Target Product Profile
EB06 Positioning – Target Product Profile Addressing Unmet Needs in Vitiligo Topical JAK Inhibitors Oral JAK Inhibitors Biologics (e.g. Ruxolitinib) (e.g. Upadacitinib, Ritlecitinib, Povorcitinib) (e.g. EB06, FB102, TEV-408) Treats lesional and non-lesional skin Viable for patients with >10% BSA No
Slide 11: EB06: Anti-CXCL10 Monoclonal Antibody Summary and Next Steps
EB06: Anti-CXCL10 Monoclonal Antibody Summary and Next Steps Targeted Mechanism of Action 65 Subjects Dosed Biological Activity Manufacturing Phase 2 Study Binds free and bound CXCL10 No Significant AEs Demonstrated Leading CDMO CTA Approved UPDATE & NEXT STEPS* Site activations and recruitment 80 p
Slide 12: Paridiprubart
Paridiprubart Potential First-in-Class Anti-TLR4 mAb
Slide 13: Paridiprubart – Anti-Toll-like Receptor (TLR4) Antibody
Paridiprubart – Anti-Toll-like Receptor 4 (TLR4) Antibody First-in-Class mAb that Specifically Blocks TLR4 Signaling 1 Paridiprubart interferes with TLR4 dimerization in a ligand independent manner Drug Profile NFκB AP-1 IRF3 A humanized IgG1k monoclonal antibody Binds to TLR4 with high affinity IL-
Slide 14: ARDS - A Significant Burden and Market Opportunity
ARDS - A Significant Burden and Market Opportunity Total Addressable Market Disease Burden 600,000 7 to 21 days $100K+ Estimated ARDS-Related of ICU stay for surviving average cost per patient ICU Admissions/Year ARDS patients1 in the US2 v v ARDS across the 7 major markets ARDS was historically und
Slide 15: Phase 3 Patient Population
Phase 3 Patient Population Baseline Characteristics A total of 104 patients hospitalized in the ICU and under invasive mechanical ventilation Patients were required to have a positive Sars-Cov2 test 5% (N=5) IMV Only 36% (N=37) Clinical ARDS Moderate 38% 55% Severe Severity 64% (N=40) Severity (N=57
Slide 16: Phase 3 Results – Primary Endpoint 28-Day Mortality
Phase 3 Results – Primary Endpoint 28-Day Mortality Paridiprubart Met Primary and Secondary Endpoints with Statistical Significance Mortality at Day 28* Mortality at Day 60* Summary of Phase 3 Results n=104 n=104 P Value <0.001 P Value =0.003 28-Day Mortality Rate: Paridiprubart demonstrated 52% a r
Slide 17: Paridiprubart Treatment Was Observed to Have Significant Impact on Clinical Improvement
Paridiprubart Treatment Was Observed to Have Significant Impact on Clinical Improvement Treatment Nearly Doubled the Chance of Recovery by Day 28 - ITT Estimated Proportion Achieving a 2-pt Reduction in WHO Scale (p<0.05) Secondary Endpoint Proportion of Patients Who Achieved at Least a 40% 2-Point
Slide 18: Phase 3 Study – Additional Analysis
Phase 3 Study – Additional Analysis Survival Benefit Observed in Broader Population, Across Severity Groups and in Subjects with Serious Comorbidities EXPLORATORY ANALYSIS2 Full Treatment Population1 (n=278) Non-IMV Pneumonia Sepsis (n=174) (n=108) (n=41) 35% 70% 25% 60% 27% Estimated Risk of Mortal
Slide 19: Exploratory Analysis of Patients with AKI and Respiratory Distress
Exploratory Analysis of 101 Patients with AKI and Respiratory Distress Utilizing the Same Multivariate Methodology Prespecified in the Phase 3 Statistical Analysis Plan Adjusted 28-Day Mortality Rate 2 Adjusted MAKE30 Incidence 2 Phase 2/31 (p<0.005) (p<0.005) Patients with Respiratory Distress (N=6
Slide 20: Govt.-Funded Support for Paridiprubart
Govt.-Funded Support for Paridiprubart U.S. Platform Study of Biodefense and Pandemic Preparedness Host Directed Therapeutics $117 million C$23 Million Phase 2 United States Government Government of Canada Status Enrolling Primary Endpoint 28-Day Mortality U.S. allocated $117M* tov evaluate three no
Slide 21: Daniluromer
Daniluromer Potential First-in-Class sPLA2 Inhibitor
Slide 22: Allergic Contact Dermatitis (ACD)
Allergic Contact Dermatitis (ACD) The Leading Occupational Health Issue Related to Dermatology Chronic ACD Represents a Significant Unmet Need 3,000+ ~70% 0 Contact Unable to fully No Known ACD is a Type IV Hypersensitivity Reaction Allergens avoid allergen Labelled Drugs Immune system sensitized fo
Slide 23: Daniluromer Market Positioning – Target Product Profile
Daniluromer Market Positioning – Target Product Profile Edesa’s Cream is Being Developed to Address a Significant Unmet Need that Exists for Chronic ACD Patients Corticosteroids TCIs Daniluromer* Viable for acute ACD patients Daniluromer Cream Viable for chronic ACD patients Observed to be safe for
Slide 24: Phase 2B Results - Composite CDSI and ISGA Scores
Phase 2B Results - – Composite CDSI and ISGA Scores 1.0% Daniluromer Met Primary Endpoint and a Key Secondary Endpoint with Statistical Significance Total CDSI Score* Total ISGA Score* Summary of Results Mean % Improvement from Baseline % Patients with a ≥2 Point Improvement from Baseline P Value =
Slide 25: Highlights and Company Outlook
Highlights and Company Outlook* Potential First-in-Class Therapeutics for Immuno-Inflammatory Diseases Significant Transactions in this Therapeutic Area and Pathway EB06 Potential Safety & Efficacy Differentiation from Current Treatment Paradigm Vitiligo Study Initiation Expected Mid-2026 Met
Slide 26: Experienced Leadership Team
Experienced Leadership Team Pharmaceutical Pipelines, Corporate Development & Strategic Transactions Executive Management Team Par Nijhawan, MD, FRCPC, AGAF Michael Brooks, PhD Peter Weiler CEO and Board Director President Chief Financial Officer Gary Koppenjan Blair Gordon, PhD VP, Corporate Affair
Slide 27: www.EdesaBiotech.com
www.EdesaBiotech.com investors@edesabiotech.com